Introduction
Preclinical evidence for the role of the immune system in cancer and in response to chemotherapy and radiotherapy
Drug | Target | Immunological effects and model used | Reference |
---|---|---|---|
Gemcitabine | Nucleoside analogue, prevents DNA replication | Reduction in the number of MDSCs | [126] |
HER2/neu model; breast cancer | |||
Mesothelioma and lung cancer models | [48] | ||
Reduction in MDSCs and Tregs when given with cyclophosphamide; CT26 colon carcinoma | [49] | ||
Reduction of Tregs in patients with pancreatic cancer | |||
Cyclophosphamide | DNA alkylation, cross-links DNA | Induction of immunogenic cell death, IFN-I mediated activation of dendritic cells; EG7 thymoma, B16F10 melanoma | [129] |
Selective depletion of Tregs in MMTV-neu mice (breast cancer) | [88] | ||
Selective depletion of Tregs in colon carcinoma model | [42] | ||
Selective depletion of Tregs in melanoma model | [130] | ||
Reduction in MDSCs and Tregs when given with gemcitabine; CT26 colon carcinoma | [48] | ||
Paclitaxel | Inhibition of mitosis through tubulin targeting | Reduction in MDSC frequency and suppressive activity | [131] |
Reduction in Treg numbers and suppressive activity | |||
Anthracyclines | Multiple mechanisms | Induction of immunogenic cell death; thymoma model, CT26 colon carcinoma | [45] |
Differentiation of CD11b+ LY6C+ APCs; MCA205 fibrosarcoma | [133] | ||
Elimination of MDSCs; 4 T1 and EMT6 breast tumor cell lines | [134] | ||
Oxaliplatin | Cross-links DNA | Induction of immunogenic cell death resulting in the activation of myeloid cells; thymoma/colon cancer model | |
Cisplatin | Cross-links DNA | Induce the accumulation of CD11c+ inflammatory dendritic cells; lung/colon carcinoma models | [136] |
Docetaxel | Inhibition of mitosis through tubulin targeting | Reduction in MDSC frequency and suppressive activity; B16 melanoma model | [116] |
5-aza-2′-deoxycytidine | DNA methyltransferase inhibition | Increased antigen presentation by tumor cells; 4 T1 breast cancer model | [137] |
Reduction in MDSCs and suppressive function; lung/prostrate carcinoma | [138] |
Observations on the prognostic value of TILs in breast cancer
Breast cancer subtype (Number of patients) | TILs predictive of pCR? | TILs predictive of disease-free or overall survival? | Reference | Chemotherapy used |
---|---|---|---|---|
All patients (56) | Yes | ND | [60] | Anthracycline/taxane or epirubicin, cyclophosphamide, and capecitabine |
All patients (73) | Yes | ND | [139] | Anthracycline/taxane based |
ER+/PR+ (659) | Yes | ND | [59] | Anthracycline/cyclophosphamide/taxane |
ER−PR− (266) | Yes | ND | ||
All patients (1334) | Yes (total or distant stromal CD8+) | [75] | Cyclophosphamide/methotrexate/fluorouracil | |
ER+ (911) | No (intratumoral or adjacent stroma CD8+) | |||
ER− (485) | No (total CD8+) | |||
HER2+ (169) | Yes (total CD8+) | |||
HER2− (1106) | No (total CD8+) | |||
Yes (total CD8+) | ||||
ER− (268) | Yes | Yes | [38] | Fluorouracil/epirubicin/cyclophosphamide or docetaxel and docetaxel plus epirubicin |
One cohort of 113, one of 255 | ||||
All patients (3403) | No | [140] | Adjuvant systemic therapy | |
ER− (927) | Yes | |||
ER+ (2456) | No | |||
HER2+ (216) | No | |||
TNBC (535) | Yes | |||
All patients (180) | Yes | ND | [37] | Anthracycline/cyclophosphamide or cyclophosphamide/epirubicin/5-fluorouracil |
TNBC (82) | Yes | ND | ||
HER2+ER−PR− (42) | No | ND | ||
HER2−ER+/PR+ (46) | No | ND | ||
All patients (845) | Yes | ND | [61] | Meta-analysis: anthracycline with or without taxane-based NAC |
ER−HER2− | Yes | ND | ||
HER2+ (116) | Yes | ND | ||
ER+Her2− | Yes | ND | ||
All patients (68) | Yes | ND | [141] | Anthracycline and/or taxane-based treatment |
All patients (180) | Yes | ND | [71] | Paclitaxel then fluorouracil/epirubicin/cyclophosphamide |
HER2− (313) | Yes | ND | [63] | Anthracycline/taxane |
All patients (2009) | ND | No | [39] | Doxorubicin followed by three cycles of cyclophosphamide/methotrexate/fluorouracil |
ER−/HER2− (1079) | ND | No | ||
HER2+ (297) | ND | No | ||
TNBC (256) | ND | Yes | ||
All patients (153) | Yes | ND | [72] | Anthracycline and/or taxane-based treatment |
TNBC (38) | Yes | |||
Non-TNBC (115) | Yes (If CD8+ component analyzed), No if CD4+ analyzed | |||
All patients (175) | Yes | ND | [73] | Anthracycline and/or taxane-based treatment or herceptin+NAC |
All patients (12439) | ND | ND | [142] | Cyclophosphamide/methotrexate/fluorouracil or epirubicin plus fluorouracil |
ER− (3591) | ND | Yes | ||
ER+ (8775) | ND | No | ||
ER+HER2+ (772) | ND | Yes | ||
All patients (934) | ND | No | [65] | Docetaxel or vinorelbine, followed by three cycles of fluorouracil/epirubicin/cyclophosphamide |
ER+HER2− (591) | ND | No | ||
HER2+ (209) | ND | No | ||
TNBC (134) | ND | Yes | ||
TNBC (278) | Yes | Yes | [64] | Anthracycline-based neoadjuvant or anthracycline/taxane |
TNBC (47) | Yes | ND | [143] | Panitumumab plus anthracycline/taxane-based chemotherapy |
TNBC (481) | ND | Yes | [66] | Doxorubicin plus cyclophosphamide and taxol/docetaxol |
All patients (580) | Yes | ND | [41] | Anthracycline/taxane with or without carboplatin |
TNBC (314) | Yes | ND | ||
HER2+ (266) | Yes |